Cited 92 times in
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조상래 | - |
dc.date.accessioned | 2015-04-24T17:17:37Z | - |
dc.date.available | 2015-04-24T17:17:37Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0305-7453 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/105123 | - |
dc.description.abstract | BACKGROUND: Although previous studies have suggested that linezolid may be effective for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), the optimal dose of linezolid for intractable MDR/XDR-TB is not clear. METHODS: Twenty-four patients with intractable MDR/XDR-TB were treated with a daily 300 mg dose of linezolid as part of their anti-TB drug regimen. RESULTS: The patients were treated with linezolid for a median duration of 359 days [interquartile range (IQR) 268-443 days]. Seventeen (71%) patients received 300 mg of linezolid once daily from the beginning of treatment for a median duration of 289 days (IQR 233-405 days). Of these patients, four developed peripheral neuropathy, one of whom discontinued linezolid. In seven (29%) patients, 600 mg/day linezolid was administered initially for a median duration of 104 days (IQR 26-145 days) followed by 300 mg/day linezolid for a median duration of 348 days (IQR 298-427 days). In five of these seven patients, the reason for changing from 600 to 300 mg/day was due to side effects of 600 mg/day linezolid (peripheral neuropathy in four patients and leucopenia in one patient). After reducing the dose to 300 mg/day, linezolid could be continued in six of the seven patients. Negative sputum conversion was achieved in 22 (92%) patients after a median of 89 days from the start of linezolid treatment (IQR 48-160 days). CONCLUSIONS: A daily 300 mg dose of linezolid may be useful for increasing the chances of culture conversion in the treatment of patients with intractable MDR/XDR-TB and might have fewer side effects, especially neurotoxicity, compared with a daily 600 mg dose of linezolid therapy. The present results encourage further research into the use of a 300 mg dose of linezolid for MDR/XDR-TB patients | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 388~391 | - |
dc.relation.isPartOf | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Acetamides/administration & dosage* | - |
dc.subject.MESH | Acetamides/adverse effects | - |
dc.subject.MESH | Acetamides/therapeutic use* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antitubercular Agents/administration & dosage* | - |
dc.subject.MESH | Antitubercular Agents/adverse effects | - |
dc.subject.MESH | Antitubercular Agents/therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Linezolid | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Oxazolidinones/administration & dosage* | - |
dc.subject.MESH | Oxazolidinones/adverse effects | - |
dc.subject.MESH | Oxazolidinones/therapeutic use* | - |
dc.subject.MESH | Sputum/microbiology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tuberculosis, Multidrug-Resistant/drug therapy* | - |
dc.title | Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Microbiology (미생물학) | - |
dc.contributor.googleauthor | Won-Jung Koh | - |
dc.contributor.googleauthor | O. Jung Kwon | - |
dc.contributor.googleauthor | Hyesun Gwak | - |
dc.contributor.googleauthor | Joo Won Chung | - |
dc.contributor.googleauthor | Sang-Nae Cho | - |
dc.contributor.googleauthor | Woo Sung Kim | - |
dc.contributor.googleauthor | Tae Sun Shim | - |
dc.identifier.doi | 10.1093/jac/dkp171 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03824 | - |
dc.relation.journalcode | J01237 | - |
dc.identifier.eissn | 1460-2091 | - |
dc.identifier.pmid | 19468028 | - |
dc.subject.keyword | MDR-TB | - |
dc.subject.keyword | XDR-TB | - |
dc.subject.keyword | oxazolidinones | - |
dc.subject.keyword | efficacy | - |
dc.subject.keyword | tolerability | - |
dc.contributor.alternativeName | Cho, Sang Nae | - |
dc.contributor.affiliatedAuthor | Cho, Sang Nae | - |
dc.citation.volume | 64 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 388 | - |
dc.citation.endPage | 391 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, Vol.64(2) : 388-391, 2009 | - |
dc.identifier.rimsid | 56766 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.